Construction And Real Estate Tenders

Medicines with the Active Ingredient Lisdexamfetamine (Atc: N06ba12)

Conclusion of Contracts for Special Care in Accordance with Section 140A Sgb V for Digital Colon Cancer Screening with the Possibility of Conclusion at any Time as Part of the So-Called Open House Procedure

Conclusion not Excluding Drug Discount Agreement. According to § 130A Paragraph 8 Sgb V by Means of an Open House Model for the Ws Lanthanum (Iii) Carbonate in the Dosage Form Chewable. (Atc Code According to Who: V03ae03)

Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Peginterferon Beta-1A (Atc Code According to Who: L03ab13)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Clonazepam, Atc N03ae01 (Obg) for the Period August 1St, 2024 - July 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Olanzapine (Excl. Dafo. for the Production of a Depot - Isu, Atc N05ah03 (Obo) F. 01.08.24 - 31.07.26

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Lisdexamfetamine, Atc N06ba12 (Obg) for the Period August 1, 2024 - July 31, 25 (Plus Extension Option 1X12 Months)

Medicines with the Active Ingredient Ustekinumab (Atc: L04ac05)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Albendazole, Atc P02ca03 (Obg) for the Period August 1St, 2024 - July 31St, 2026

Medicines with the Active Ingredient Lanthanum (Iii) Carbonate (Atc: V03ae03 - in the Dosage Form Chewable Tablets)